Value of 18F-FDG PET/CT imaging in the staging, restaging, monitoring of response to therapy and surveillance of uterine leiomyosarcomas. Issue 7 (July 2018)
- Record Type:
- Journal Article
- Title:
- Value of 18F-FDG PET/CT imaging in the staging, restaging, monitoring of response to therapy and surveillance of uterine leiomyosarcomas. Issue 7 (July 2018)
- Main Title:
- Value of 18F-FDG PET/CT imaging in the staging, restaging, monitoring of response to therapy and surveillance of uterine leiomyosarcomas
- Authors:
- Bélissant, Ophélie
Champion, Laurence
Thevenet, Hind
Weinmann, Pierre
Alberini, Jean-Louis - Abstract:
- Abstract : Objective: Leiomyosarcoma (LMS) is the most common subtype of uterine sarcomas. It is a rare and aggressive tumour. The aim of the present study was to assess the performance of fluorine-18-fluorodeoxyglucose ( 18 F-FDG) PET/CT imaging in four clinical settings: initial staging, restaging, monitoring of response to therapy and post-therapy surveillance of uterine LMS. Patients and methods: A bicentric retrospective study was carried out on a group of 21 patients with uterine LMS for whom a total of 52 PET/CT scans were available in initial staging ( n =11), restaging ( n =11), monitoring of response to therapy ( n =17) and post-therapy surveillance ( n =13). Clinical (minimum 6 months after PET/CT scan) and/or imaging follow-up and pathology were used as the reference standard. Results: In the initial staging, the sensitivity, specificity and accuracy of PET imaging were 80, 100 and 91%, respectively. In the restaging and monitoring of response to therapy, all these indices were 100%, whereas they were lower in post-therapy surveillance at 75, 100 and 85%, respectively, because of two false-negative results. False-negative lesions were an infracentimetric lung nodule in the initial staging and a peritoneal nodule that had increased in size between two PET/CT scans in post-therapy surveillance. PET-negative lesions were all identified on the computed tomography (CT) part of the PET/CT; thus, the performances of the exam improved to 100% on taking into account theAbstract : Objective: Leiomyosarcoma (LMS) is the most common subtype of uterine sarcomas. It is a rare and aggressive tumour. The aim of the present study was to assess the performance of fluorine-18-fluorodeoxyglucose ( 18 F-FDG) PET/CT imaging in four clinical settings: initial staging, restaging, monitoring of response to therapy and post-therapy surveillance of uterine LMS. Patients and methods: A bicentric retrospective study was carried out on a group of 21 patients with uterine LMS for whom a total of 52 PET/CT scans were available in initial staging ( n =11), restaging ( n =11), monitoring of response to therapy ( n =17) and post-therapy surveillance ( n =13). Clinical (minimum 6 months after PET/CT scan) and/or imaging follow-up and pathology were used as the reference standard. Results: In the initial staging, the sensitivity, specificity and accuracy of PET imaging were 80, 100 and 91%, respectively. In the restaging and monitoring of response to therapy, all these indices were 100%, whereas they were lower in post-therapy surveillance at 75, 100 and 85%, respectively, because of two false-negative results. False-negative lesions were an infracentimetric lung nodule in the initial staging and a peritoneal nodule that had increased in size between two PET/CT scans in post-therapy surveillance. PET-negative lesions were all identified on the computed tomography (CT) part of the PET/CT; thus, the performances of the exam improved to 100% on taking into account the CT component of the PET/CT. Conclusion: PET/CT imaging has a high diagnostic yield in the initial staging and restaging of uterine LMS, but seems less sensitive in post-therapy surveillance. Evaluation of the CT part improves the sensitivity of the PET scan. Thus, PET/CT imaging should be considered in patients presenting with LMS. … (more)
- Is Part Of:
- Nuclear medicine communications. Volume 39:Issue 7(2018:Jul.)
- Journal:
- Nuclear medicine communications
- Issue:
- Volume 39:Issue 7(2018:Jul.)
- Issue Display:
- Volume 39, Issue 7 (2018)
- Year:
- 2018
- Volume:
- 39
- Issue:
- 7
- Issue Sort Value:
- 2018-0039-0007-0000
- Page Start:
- Page End:
- Publication Date:
- 2018-07
- Subjects:
- 18F-FDG PET/CT -- performances -- sarcoma -- staging -- surveillance -- therapy -- uterine leiomyosarcoma
Nuclear medicine -- Periodicals
616.07575 - Journal URLs:
- http://journals.lww.com/nuclearmedicinecomm/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
http://www.lww.com/Product/0143-3636 ↗ - DOI:
- 10.1097/MNM.0000000000000848 ↗
- Languages:
- English
- ISSNs:
- 0143-3636
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6180.923000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 10527.xml